Chloride Channel Agonists
"Chloride Channel Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that stimulate chloride ion influx through cell membrane channels.
Descriptor ID |
D065101
|
MeSH Number(s) |
D27.505.519.562.311
|
Concept/Terms |
Chloride Channel Agonists- Chloride Channel Agonists
- Agonists, Chloride Channel
- Channel Agonists, Chloride
- Chloride Channel Activators
- Activators, Chloride Channel
- Channel Activators, Chloride
- Chloride Channel Stimulators
- Channel Stimulators, Chloride
- Stimulators, Chloride Channel
|
Below are MeSH descriptors whose meaning is more general than "Chloride Channel Agonists".
Below are MeSH descriptors whose meaning is more specific than "Chloride Channel Agonists".
This graph shows the total number of publications written about "Chloride Channel Agonists" by people in this website by year, and whether "Chloride Channel Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
2019 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chloride Channel Agonists" by people in Profiles.
-
Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. Chest. 2021 10; 160(4):1232-1240.
-
Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series. J Cyst Fibros. 2021 05; 20(3):399-401.
-
Treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2020 11; 26(6):679-684.
-
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713.
-
Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Ann Am Thorac Soc. 2018 08; 15(8):897-902.
-
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 01; 17(1):83-88.